NKTR
Nektar Therapeutics
40.30$
+0.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -2.5% | -2.7% | -9.2% | -31.9% | -66.6% | +28.3% | -253.8% | – | -290.8% | – | +3.3% | – | |
| – | -11.0% | -17.3% | -9.7% | -0.5% | -10.9% | -18.8% | -10.6% | -11.9% | -28.6% | +53.0% | +0.3% | – | |
| – | – | – | – | -90.2% | -1,183.3% | – | – | – | – | – | – | – | |
| – | +618.2% | -33.8% | +18.5% | +258.1% | -31.1% | -99.6% | +1,750.0% | +208.1% | -84.2% | +0.0% | +522.2% | – | |
| – | -69.2% | +10.8% | -11.8% | +171.6% | +30.6% | -27.4% | +13.6% | -291.2% | – | -94,398.1% | +13.8% | – | |
| – | – | – | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | – | +349,925.0% | -100.0% | -31.6% | +538.5% | -91.6% | +2,914.3% | +67,045.5% | -72.7% | +1,269.4% | -31.2% | – | |
| – | -308.4% | – | -242.8% | – | +560.0% | -137.9% | – | -147.8% | – | – | -185.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.